IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, is now available from the biopharmaceutical company Ardelyx. The first of its Ardelyx products approved by the US Food and Drug Administration is IBSRELA.
Indegene, a provider of technology-driven healthcare solutions, and meta Me Health, the manufacturer of Regulora and a prescription digital therapy (PDT) company, have announced that Regulora is a drug for the treatment of stomach pain (IBS) associated with irritable bowel syndrome.
Author Credits: Dhruv Bhatia
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?